» Articles » PMID: 25284317

The Complex Relationships Between Microglia, Alpha-synuclein, and LRRK2 in Parkinson's Disease

Overview
Journal Neuroscience
Specialty Neurology
Date 2014 Oct 7
PMID 25284317
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

The proteins alpha-synuclein (αSyn) and leucine rich repeat kinase 2 (LRRK2) are both key players in the pathogenesis of the neurodegenerative disorder Parkinson's disease (PD), but establishing a functional link between the two proteins has proven elusive. Research studies for these two proteins have traditionally and justifiably focused in neuronal cells, but recent studies indicate that each protein could play a greater pathological role elsewhere. αSyn is expressed at high levels within neurons, but they also secrete the protein into the extracellular milieu, where it can have broad ranging effects in the nervous system and relevance to disease etiology. Similarly, low neuronal LRRK2 expression and activity suggests that LRRK2-related functions could be more relevant in cells with higher expression, such as brain-resident microglia. Microglia are monocytic immune cells that protect neurons from noxious stimuli, including pathological αSyn species, and microglial activation is believed to contribute to neuroinflammation and neuronal death in PD. Interestingly, both αSyn and LRRK2 can be linked to microglial function. Secreted αSyn can directly activate microglia, and can be taken up by microglia for clearance, while LRRK2 has been implicated in the intrinsic regulation of microglial activation and of lysosomal degradation processes. Based on these observations, the present review will focus on how PD-associated mutations in LRRK2 could potentially alter microglial biology with respect to neuronally secreted αSyn, resulting in cell dysfunction and neurodegeneration.

Citing Articles

LRRK2 mutation contributes to decreased free water in the nucleus basalis of Meynert in manifest and premanifest Parkinson's disease.

Wang C, Wang S, Zhou C, Wu C, Yang S, Xu X J Neurol. 2024; 272(1):33.

PMID: 39666095 DOI: 10.1007/s00415-024-12811-5.


Revolutionizing our understanding of Parkinson's disease: Dr. Heinz Reichmann's pioneering research and future research direction.

Tanaka M, Vecsei L J Neural Transm (Vienna). 2024; 131(12):1367-1387.

PMID: 39110245 PMC: 11608389. DOI: 10.1007/s00702-024-02812-z.


Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain.

Singh V, Menard M, Serrano G, Beach T, Zhao H, Riley-DiPaolo A Acta Neuropathol Commun. 2023; 11(1):201.

PMID: 38110990 PMC: 10726543. DOI: 10.1186/s40478-023-01704-9.


Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease.

Lv Q, Tao K, Wang X, Yao X, Pang M, Liu J Inflamm Res. 2023; 72(3):443-462.

PMID: 36598534 DOI: 10.1007/s00011-022-01676-x.


Mechanisms of Autoimmune Cell in DA Neuron Apoptosis of Parkinson's Disease: Recent Advancement.

Zheng Z, Zhang S, Zhang H, Gao Z, Wang X, Liu X Oxid Med Cell Longev. 2022; 2022:7965433.

PMID: 36567855 PMC: 9771667. DOI: 10.1155/2022/7965433.


References
1.
Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

2.
Lashuel H, Overk C, Oueslati A, Masliah E . The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012; 14(1):38-48. PMC: 4295774. DOI: 10.1038/nrn3406. View

3.
Cookson M . alpha-Synuclein and neuronal cell death. Mol Neurodegener. 2009; 4:9. PMC: 2646729. DOI: 10.1186/1750-1326-4-9. View

4.
Bonilla D, Bhattacharya A, Sha Y, Xu Y, Xiang Q, Kan A . Autophagy regulates phagocytosis by modulating the expression of scavenger receptors. Immunity. 2013; 39(3):537-47. PMC: 8059138. DOI: 10.1016/j.immuni.2013.08.026. View

5.
Fauvet B, Mbefo M, Fares M, Desobry C, Michael S, Ardah M . α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012; 287(19):15345-64. PMC: 3346117. DOI: 10.1074/jbc.M111.318949. View